Loading…
Reported covered position: Pro Staff, House Merchant Marine & Fisheries
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SHIRE PHARMACEUTICALS LLC via STANTON PARK GROUP
2016 · fourth_quarter · Q4
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers Drug pricing, including the Part B Demonstration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| VERTEX PHARMACEUTICALS INCORPORATED |
| 16 |
| 2013–2016 |
| PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION | 13 | 2013–2016 |
| HOLCIM (US) INC. | 12 | 2013–2015 |
| SCRIBEAMERICA | 12 | 2014–2016 |
| WESTERN FUELS ASSOCIATION, INC. | 12 | 2013–2015 |
| HENDERSON-COLUMBIA CORP. AND THE ESTATE OF WILBUR C. HENDERSON | 10 | 2014–2016 |
| SHIRE PHARMACEUTICALS LLC | 9 | 2015–2016 |
| GOVERNMENT TRANSACTION SERVICES | 8 | 2014–2015 |
| JUNIPER NETWORKS (US), INC. | 8 | 2015–2016 |
| ENERGY DEFENSE POWER SYSTEMS | 7 | 2013–2014 |
| HORIZON SOFTWARE INTERNATIONAL | 7 | 2015–2016 |
| ALLIANCE OF HEALTHCARE SHARING MINISTRIES | 6 | 2015–2016 |
| NATIONAL KIDNEY FOUNDATION | 6 | 2015–2016 |
| VERISIGN | 6 | 2013–2014 |
| ALKERMES, INC. | 5 | 2013–2014 |
| MICROSOFT CORPORATION | 5 | 2013–2014 |
| BAYER MATERIAL SCIENCE LLC | 4 | 2015 |
| ADAMIS PHARMACEUTICALS CORPORATION | 3 | 2015–2016 |
| ALLIANCE OF AUTOMOBILE MANUFACTURERS | 3 | 2016 |
| THE CLAREMONT GROUP | 3 | 2014 |
| PRASIDIUX, INC. | 2 | 2013 |
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers Drug pricing, including the Part B Demonstration
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
To amend the Internal Revenue Code of 1986 to make members of health care sharing ministries eligible to establish health savings accounts.
Client: ALLIANCE OF HEALTHCARE SHARING MINISTRIES · Firm: STANTON PARK GROUP
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
To amend the Internal Revenue Code of 1986 to make members of health care sharing ministries eligible to establish health savings accounts.
Client: ALLIANCE OF HEALTHCARE SHARING MINISTRIES · Firm: STANTON PARK GROUP
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
To amend the Internal Revenue Code of 1986 to make members of health care sharing ministries eligible to establish health savings accounts.
Client: ALLIANCE OF HEALTHCARE SHARING MINISTRIES · Firm: STANTON PARK GROUP
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
To amend the Internal Revenue Code of 1986 to make members of health care sharing ministries eligible to establish health savings accounts.
Client: ALLIANCE OF HEALTHCARE SHARING MINISTRIES · Firm: STANTON PARK GROUP
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
Medicare Access and CHIP Reauthorization Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement
Medicare Access and CHIP Reauthorization Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
Medicare Access and CHIP Reauthorization Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
Medicare Access and CHIP Reauthorization Act of 2015
Client: PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION · Firm: STANTON PARK GROUP
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act). Value Based Purchasing
Medicare Access and CHIP Reauthorization Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Medicare Patient Access to Cancer Treatment Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
Medicare Patient Access to Cancer Treatment Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
Medicare Patient Access to Cancer Treatment Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement
Medicare Patient Access to Cancer Treatment Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
21st Century Cures Act
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers Drug pricing, including the Part B Demonstration
21st Century Cures Act
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
21st Century Cures Act
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
21st Century Cures Act
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers Drug pricing, including the Part B Demonstration
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers Drug pricing, including the Part B Demonstration
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act 21st Century Cures - advancing cures for orphan diseases
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: STANTON PARK GROUP
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: STANTON PARK GROUP
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: STANTON PARK GROUP
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: STANTON PARK GROUP
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Maximizing Efficiency and Improving Access to Providers at the Department of Veterans Affairs Act of 2016
Client: SCRIBEAMERICA · Firm: STANTON PARK GROUP
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration S.3035, requiring the Department of Veterans Affairs (VA) to carry out a pilot program for the contract hiring of medical scribes so that physicians can spend more time with their veteran patients and improve the quality of every VA health care appointment
Maximizing Efficiency and Improving Access to Providers at the Department of Veterans Affairs Act of 2016
Client: SCRIBEAMERICA · Firm: STANTON PARK GROUP
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration S.3035, requiring the Department of Veterans Affairs (VA) to carry out a pilot program for the contract hiring of medical scribes so that physicians can spend more time with their veteran patients and improve the quality of every VA health care appointment
Maximizing Efficiency and Improving Access to Providers at the Department of Veterans Affairs Act of 2016
Client: SCRIBEAMERICA · Firm: STANTON PARK GROUP
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration S.3035, requiring the Department of Veterans Affairs (VA) to carry out a pilot program for the contract hiring of medical scribes so that physicians can spend more time with their veteran patients and improve the quality of every VA health care appointment
Improving Child Nutrition Integrity and Access Act of 2016
Client: HORIZON SOFTWARE INTERNATIONAL · Firm: STANTON PARK GROUP
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA S 3136, Child Nutrition Reauthorization
Improving Child Nutrition Integrity and Access Act of 2016
Client: HORIZON SOFTWARE INTERNATIONAL · Firm: STANTON PARK GROUP
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA S 3136, Child Nutrition Reauthorization
Improving Child Nutrition Integrity and Access Act of 2016
Client: HORIZON SOFTWARE INTERNATIONAL · Firm: STANTON PARK GROUP
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA S 3136, Child Nutrition Reauthorization
Energy Savings and Building Efficiency Act of 2015
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535). The Energy Savings and Buildings Efficiency Act of 2015 (HR 1273). The Portman Shaheen Energy Savings and Industrial Competitiveness Act (S 720). Energy efficiency provisions of the FY2016 Energy and Water Appropriations Act (HR 2028 and Senate draft).
Energy Savings and Building Efficiency Act of 2015
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535). The Energy Savings and Buildings Efficiency Act of 2015 (HR 1273). The Portman Shaheen Energy Savings and Industrial Competitiveness Act (S 720). Energy efficiency provisions of the FY2016 Energy and Water Appropriations Act (HR 2028 and Senate draft).
To amend the Internal Revenue Code of 1986 to make members of health care sharing ministries eligible to establish health savings accounts.
Client: ALLIANCE OF HEALTHCARE SHARING MINISTRIES · Firm: STANTON PARK GROUP
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
Medicare Access and CHIP Reauthorization Act of 2015
Client: INSIGNIA HEALTH · Firm: STANTON PARK GROUP
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness; HR 2 - the Medicare Access and CHIP Reauthorization Act
Medicare Access and CHIP Reauthorization Act of 2015
Client: PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION · Firm: STANTON PARK GROUP
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act). Value Based Purchasing
Medicare Access and CHIP Reauthorization Act of 2015
Client: INSIGNIA HEALTH · Firm: STANTON PARK GROUP
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness; HR 2 - the Medicare Access and CHIP Reauthorization Act
Medicare Access and CHIP Reauthorization Act of 2015
Client: INSIGNIA HEALTH · Firm: STANTON PARK GROUP
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness; HR 2 - the Medicare Access and CHIP Reauthorization Act
Medicare Access and CHIP Reauthorization Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
Medicare Access and CHIP Reauthorization Act of 2015
Client: INSIGNIA HEALTH · Firm: STANTON PARK GROUP
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness; HR 2 - the Medicare Access and CHIP Reauthorization Act
Medicare Access and CHIP Reauthorization Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
Medicare Access and CHIP Reauthorization Act of 2015
Client: PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION · Firm: STANTON PARK GROUP
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act). Value Based Purchasing
Medicare Access and CHIP Reauthorization Act of 2015
Client: PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION · Firm: STANTON PARK GROUP
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act)
Medicare Access and CHIP Reauthorization Act of 2015
Client: PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION · Firm: STANTON PARK GROUP
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act). Value Based Purchasing
Medicare Access and CHIP Reauthorization Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
Further Continuing and Security Assistance Appropriations Act, 2017
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535). The Energy Savings and Buildings Efficiency Act of 2015 (HR 1273). The Portman Shaheen Energy Savings and Industrial Competitiveness Act (S 720). Energy efficiency provisions of the FY2016 Energy and Water Appropriations Act (HR 2028 and Senate draft).
Further Continuing and Security Assistance Appropriations Act, 2017
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535). The Energy Savings and Buildings Efficiency Act of 2015 (HR 1273). The Portman Shaheen Energy Savings and Industrial Competitiveness Act (S 720). Energy efficiency provisions of the FY2016 Energy and Water Appropriations Act (HR 2028 and Senate draft).
Cutting Costly Codes Act of 2015
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535). The Energy Savings and Buildings Efficiency Act of 2015 (HR 1273). The Portman Shaheen Energy Savings and Industrial Competitiveness Act (S 720). Energy efficiency provisions of the FY2016 Energy and Water Appropriations Act (HR 2028 and Senate draft).
Cutting Costly Codes Act of 2015
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535).
Cutting Costly Codes Act of 2015
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535). The Energy Savings and Buildings Efficiency Act of 2015 (HR 1273). The Portman Shaheen Energy Savings and Industrial Competitiveness Act (S 720). Energy efficiency provisions of the FY2016 Energy and Water Appropriations Act (HR 2028 and Senate draft).
Defending Public Safety Employees' Retirement Act
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
Trade Promotion Authority, including HR 2146, Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Defending Public Safety Employees' Retirement Act
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
Trade Promotion Authority, including HR 2146, Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Defending Public Safety Employees' Retirement Act
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
Trade Promotion Authority, including HR 2146, Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Defending Public Safety Employees' Retirement Act
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
Trade Promotion Authority, including HR 2146, Bipartisan Congressional Trade Priorities and Accountability Act of 2015
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. Safety Through Informed Consumers (STICRS) HR 2702/S1535 HR 22, the FAST Act
infrastructure spending; concrete and cement standards for construction; reauthorization of transportation research programs; closure of the Upper St. Anthony Falls lock and dam, as enacted in the Water Resources and Development Act; the Federal Motor Carrier Safety Administration (FMCSA) rest-break and hours-of-service requirements for ready mix concrete drivers S. 1732, the Comprehensive Transportation and Consumer Protection Act of 2015 HR 22, the FAST Act
Frank R. Lautenberg Chemical Safety for the 21st Century Act
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action on chemical facilities regulation; Monitor legislative and administrative action related to the Toxic Substances Control Act. S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act and H.R. 2576, the TSCA Modernization Act of 2015
Frank R. Lautenberg Chemical Safety for the 21st Century Act
Client: BAYER MATERIAL SCIENCE LLC · Firm: STANTON PARK GROUP
Monitor legislative and administrative action on chemical facilities regulation; Monitor legislative and administrative action related to the Toxic Substances Control Act. S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act and H.R. 2576, the TSCA Modernization Act of 2015
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. Safety Through Informed Consumers (STICRS) HR 2702/S1535 HR 22, the FAST Act
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. Safety Through Informed Consumers (STICRS) HR 2702/S1535
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. Safety Through Informed Consumers (STICRS) HR 2702/S1535
Safety Through Informed Consumers Act of 2015
Client: DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) · Firm: STANTON PARK GROUP
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. Safety Through Informed Consumers (STICRS) HR 2702/S1535
Medicare Patient Access to Cancer Treatment Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
Medicare Patient Access to Cancer Treatment Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
Medicare Patient Access to Cancer Treatment Act of 2015
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) · Firm: STANTON PARK GROUP
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
2016 · fourth_quarter · Q4
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via STANTON PARK GROUP
2016 · fourth_quarter · Q4
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF AUTOMOBILE MANUFACTURERS via STANTON PARK GROUP
2016 · fourth_quarter · Q4
automotive safety issues, spectrum utilization, V2V communications and Dedicated Short Range Communications (DSRC)
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
TRIMBLE NAVIGATION LIMITED via STANTON PARK GROUP
2016 · fourth_quarter · Q4
spectrum issues impacting the reliability of viability of the Global Positioning System (GPS); all provisions related to GPS interface;
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE
ALLIANCE OF HEALTHCARE SHARING MINISTRIES via STANTON PARK GROUP
2016 · fourth_quarter · Q4
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via STANTON PARK GROUP
2016 · fourth_quarter · Q4
promoting payment policies that promote early detection and treatment of chronic kidney disease, and ensuring patient access to care that improves outcomes for patients with chronic kidney disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON SOFTWARE INTERNATIONAL via STANTON PARK GROUP
2016 · fourth_quarter · Q4
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA S 3136, Child Nutrition Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JUNIPER NETWORKS (US), INC. via STANTON PARK GROUP
2016 · fourth_quarter · Q4
cybersecurity, protection of critical infrastructure, and risk management of government and industry supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCRIBEAMERICA via STANTON PARK GROUP
2016 · fourth_quarter · Q4
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration S.3035, requiring the Department of Veterans Affairs (VA) to carry out a pilot program for the contract hiring of medical scribes so that physicians can spend more time with their veteran patients and improve the quality of every VA health care appointment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSIGNIA HEALTH via STANTON PARK GROUP
2016 · fourth_quarter · Q4
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLGA FOUNDATION via STANTON PARK GROUP
2016 · fourth_quarter · Q4
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act 21st Century Cures - advancing cures for orphan diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HENDERSON-COLUMBIA CORP. AND THE ESTATE OF WILBUR C. HENDERSON via STANTON PARK GROUP
2016 · fourth_quarter · Q4
oversight of the EPA and the Superfund program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FIBERTOWER via STANTON PARK GROUP
2016 · fourth_quarter · Q4
spectrum and issues impacting fixed wireless private carriers who offer broadband transport and backhaul infrastructure services. E-rate program and partnerships with schools and libraries.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) via STANTON PARK GROUP
2016 · fourth_quarter · Q4
energy and water appropriations; energy efficiency research and development
trade policies and impact on supply chain
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT)
ALLIANCE OF AUTOMOBILE MANUFACTURERS via STANTON PARK GROUP
2016 · third_quarter · Q3
automotive safety issues, spectrum utilization, V2V communications
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
NATIONAL KIDNEY FOUNDATION via STANTON PARK GROUP
2016 · third_quarter · Q3
promoting payment policies that promote early detection and treatment of chronic kidney disease, and ensuring patient access to care that improves outcomes for patients with chronic kidney disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF HEALTHCARE SHARING MINISTRIES via STANTON PARK GROUP
2016 · third_quarter · Q3
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JUNIPER NETWORKS (US), INC. via STANTON PARK GROUP
2016 · third_quarter · Q3
cybersecurity, protection of critical infrastructure, and risk management of government and industry supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via STANTON PARK GROUP
2016 · third_quarter · Q3
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HENDERSON-COLUMBIA CORP. AND THE ESTATE OF WILBUR C. HENDERSON via STANTON PARK GROUP
2016 · third_quarter · Q3
oversight of the EPA and the Superfund program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCRIBEAMERICA via STANTON PARK GROUP
2016 · third_quarter · Q3
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration S.3035, requiring the Department of Veterans Affairs (VA) to carry out a pilot program for the contract hiring of medical scribes so that physicians can spend more time with their veteran patients and improve the quality of every VA health care appointment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSIGNIA HEALTH via STANTON PARK GROUP
2016 · third_quarter · Q3
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRIMBLE NAVIGATION LIMITED via STANTON PARK GROUP
2016 · third_quarter · Q3
spectrum issues impacting the reliability of viability of the Global Positioning System (GPS); all provisions related to GPS interface;
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE
PLGA FOUNDATION via STANTON PARK GROUP
2016 · third_quarter · Q3
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON SOFTWARE INTERNATIONAL via STANTON PARK GROUP
2016 · third_quarter · Q3
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA S 3136, Child Nutrition Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via STANTON PARK GROUP
2016 · third_quarter · Q3
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FIBERTOWER via STANTON PARK GROUP
2016 · third_quarter · Q3
spectrum and issues impacting fixed wireless private carriers who offer broadband transport and backhaul infrastructure services. E-rate program and partnerships with schools and libraries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) via STANTON PARK GROUP
2016 · third_quarter · Q3
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) via STANTON PARK GROUP
2016 · third_quarter · Q3
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
energy and water appropriations; energy efficiency research and development
trade policies and impact on supply chain
Filing targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), White House Office
ALLIANCE OF AUTOMOBILE MANUFACTURERS via STANTON PARK GROUP
2016 · third_quarter · RR
spectrum allocation
JUNIPER NETWORKS (US), INC. via STANTON PARK GROUP
2016 · second_quarter · Q2
cybersecurity, protection of critical infrastructure, and risk management of government and industry supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via STANTON PARK GROUP
2016 · second_quarter · Q2
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF HEALTHCARE SHARING MINISTRIES via STANTON PARK GROUP
2016 · second_quarter · Q2
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRIMBLE NAVIGATION LIMITED via STANTON PARK GROUP
2016 · second_quarter · Q2
spectrum issues impacting the reliability of viability of the Global Positioning System (GPS); all provisions related to GPS interface;
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE
FIBERTOWER via STANTON PARK GROUP
2016 · second_quarter · Q2
spectrum and issues impacting fixed wireless private carriers who offer broadband transport and backhaul infrastructure services. E-rate program and partnerships with schools and libraries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via STANTON PARK GROUP
2016 · second_quarter · Q2
promoting payment policies that promote early detection and treatment of chronic kidney disease, and ensuring patient access to care that improves outcomes for patients with chronic kidney disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCRIBEAMERICA via STANTON PARK GROUP
2016 · second_quarter · Q2
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration S.3035, requiring the Department of Veterans Affairs (VA) to carry out a pilot program for the contract hiring of medical scribes so that physicians can spend more time with their veteran patients and improve the quality of every VA health care appointment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via STANTON PARK GROUP
2016 · second_quarter · Q2
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) via STANTON PARK GROUP
2016 · second_quarter · Q2
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) via STANTON PARK GROUP
2016 · second_quarter · Q2
trade policies and impact on supply chain
energy and water appropriations; energy efficiency research and development
vehicle safety issues, vehicle communications (V2V), dedicated short range communications, spectrum for vehicle communications, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
Filing targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), White House Office
INSIGNIA HEALTH via STANTON PARK GROUP
2016 · second_quarter · Q2
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON SOFTWARE INTERNATIONAL via STANTON PARK GROUP
2016 · second_quarter · Q2
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA S 3136, Child Nutrition Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLGA FOUNDATION via STANTON PARK GROUP
2016 · second_quarter · Q2
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HENDERSON-COLUMBIA CORP. AND THE ESTATE OF WILBUR C. HENDERSON via STANTON PARK GROUP
2016 · second_quarter · Q2
oversight of the EPA and the Superfund program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via STANTON PARK GROUP
2016 · first_quarter · Q1
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; DEA processes and re-exportation; rare disease awareness; H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRIMBLE NAVIGATION LIMITED via STANTON PARK GROUP
2016 · first_quarter · Q1
spectrum issues impacting the reliability of viability of the Global Positioning System (GPS); all provisions related to GPS interface;
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via STANTON PARK GROUP
2016 · first_quarter · Q1
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSIGNIA HEALTH via STANTON PARK GROUP
2016 · first_quarter · Q1
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JUNIPER NETWORKS (US), INC. via STANTON PARK GROUP
2016 · first_quarter · Q1
cybersecurity, protection of critical infrastructure, and risk management of government and industry supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON SOFTWARE INTERNATIONAL via STANTON PARK GROUP
2016 · first_quarter · Q1
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADAMIS PHARMACEUTICALS CORPORATION via STANTON PARK GROUP
2016 · first_quarter · Q1
patient access to products that treat anaphylaxis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via STANTON PARK GROUP
2016 · first_quarter · Q1
early detection and treatment of chronic kidney disease, and ensuring patient access to care that improves outcomes for patients with chronic kidney disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF HEALTHCARE SHARING MINISTRIES via STANTON PARK GROUP
2016 · first_quarter · Q1
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCRIBEAMERICA via STANTON PARK GROUP
2016 · first_quarter · Q1
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) via STANTON PARK GROUP
2016 · first_quarter · Q1
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLGA FOUNDATION via STANTON PARK GROUP
2016 · first_quarter · Q1
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2017 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease S. 1878, the Advancing Hope Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION via STANTON PARK GROUP
2016 · first_quarter · Q1
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act). Value Based Purchasing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HENDERSON-COLUMBIA CORP. AND THE ESTATE OF WILBUR C. HENDERSON via STANTON PARK GROUP
2016 · first_quarter · Q1
oversight of the EPA and the Superfund program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FIBERTOWER via STANTON PARK GROUP
2016 · first_quarter · Q1
spectrum and issues impacting fixed wireless private carriers who offer broadband transport and backhaul infrastructure services. E-rate program and partnerships with schools and libraries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) via STANTON PARK GROUP
2016 · first_quarter · Q1
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. implementation of the Safety Through Informed Consumers (STICRS) HR 2702/S1535 enacted as part of HR 22, the FAST Act the future of the automated vehicle
energy and water appropriations; energy efficiency research and development
trade policies and impact on supply chain
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT)
GOVERNMENT TRANSACTION SERVICES via STANTON PARK GROUP
2015 · fourth_quarter · Q4
administrative/paperwork burden reduction by simplifying and streamlining the federal grant process
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF HEALTHCARE SHARING MINISTRIES via STANTON PARK GROUP
2015 · fourth_quarter · Q4
expanding access to preventive care and wellness through Health Savings Accounts HR 1752, to make members of healthcare sharing ministries eligible to establish health savings accounts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via STANTON PARK GROUP
2015 · fourth_quarter · Q4
early detection and treatment of chronic kidney disease, and ensuring patient access to care that improves outcomes for patients with chronic kidney disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADAMIS PHARMACEUTICALS CORPORATION via STANTON PARK GROUP
2015 · fourth_quarter · Q4
raising awareness regarding high quality, low-cost solutions for patients, physicians, and healthcare organizations in the therapeutic areas of respiratory disease and allergies; and ensuring patient access to products that treat anaphylaxis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON SOFTWARE INTERNATIONAL via STANTON PARK GROUP
2015 · fourth_quarter · Q4
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JUNIPER NETWORKS (US), INC. via STANTON PARK GROUP
2015 · fourth_quarter · Q4
cybersecurity, protection of critical infrastructure, and risk management of government and industry supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via STANTON PARK GROUP
2015 · fourth_quarter · Q4
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; HR 6, the 21st Century Cures initiative; DEA processes and re-exportation; ADHD awareness; patent reform;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCRIBEAMERICA via STANTON PARK GROUP
2015 · fourth_quarter · Q4
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSIGNIA HEALTH via STANTON PARK GROUP
2015 · fourth_quarter · Q4
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness; HR 2 - the Medicare Access and CHIP Reauthorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRIMBLE NAVIGATION LIMITED via STANTON PARK GROUP
2015 · fourth_quarter · Q4
spectrum issues impacting the reliability of viability of the Global Positioning System (GPS); all provisions related to GPS interface; Financial Services and General Government Appropriations (HR 2995)
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE
WESTERN FUELS ASSOCIATION, INC. via STANTON PARK GROUP
2015 · fourth_quarter · Q4
coal issues
captive shipper issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via STANTON PARK GROUP
2015 · fourth_quarter · Q4
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) via STANTON PARK GROUP
2015 · fourth_quarter · Q4
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLGA FOUNDATION via STANTON PARK GROUP
2015 · fourth_quarter · Q4
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2016 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease HR 3020/S 1695, the FY2016 Labor HHS Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION via STANTON PARK GROUP
2015 · fourth_quarter · Q4
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act). Value Based Purchasing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOLCIM (US) INC via STANTON PARK GROUP
2015 · fourth_quarter · 4T
energy intensive industries
cement industry standards for various emissions
infrastructure spending; concrete and cement standards for construction; reauthorization of transportation research programs; closure of the Upper St. Anthony Falls lock and dam, as enacted in the Water Resources and Development Act; the Federal Motor Carrier Safety Administration (FMCSA) rest-break and hours-of-service requirements for ready mix concrete drivers S. 1732, the Comprehensive Transportation and Consumer Protection Act of 2015 HR 22, the FAST Act
HENDERSON-COLUMBIA CORP. AND THE ESTATE OF WILBUR C. HENDERSON via STANTON PARK GROUP
2015 · fourth_quarter · Q4
oversight of the EPA and the Superfund program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FIBERTOWER via STANTON PARK GROUP
2015 · fourth_quarter · Q4
spectrum and issues impacting fixed wireless private carriers who offer broadband transport and backhaul infrastructure services. E-rate program and partnerships with schools and libraries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) via STANTON PARK GROUP
2015 · fourth_quarter · Q4
Trade Promotion Authority, including HR 2146, Bipartisan Congressional Trade Priorities and Accountability Act of 2015
energy and water appropriations; energy efficiency research and development
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. Safety Through Informed Consumers (STICRS) HR 2702/S1535 HR 22, the FAST Act
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT)
NATIONAL KIDNEY FOUNDATION via STANTON PARK GROUP
2015 · fourth_quarter · RR
Early detection and treatment of chronic kidney disease, and ensuring patient access to care that improves outcomes for patients with chronic kidney disease
ALLIANCE OF HEALTHCARE SHARING MINISTRIES via STANTON PARK GROUP
2015 · fourth_quarter · RR
expanding access to preventive care and wellness through Health Savings Accounts
ADAMIS PHARMACEUTICALS CORPORATION via STANTON PARK GROUP
2015 · fourth_quarter · RR
raising awareness about high quality, low-cost solutions for patients, physicians, and healthcare organizations in the therapeutic areas of respiratory disease and allergies; and ensuring patient access to products that treat anaphylaxis
BAYER MATERIAL SCIENCE LLC via STANTON PARK GROUP
2015 · third_quarter · 3T
Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. The Energy Efficiency Improvement Act of 2015 (HR2126/S 535). The Energy Savings and Buildings Efficiency Act of 2015 (HR 1273). The Portman Shaheen Energy Savings and Industrial Competitiveness Act (S 720). Energy efficiency provisions of the FY2016 Energy and Water Appropriations Act (HR 2028 and Senate draft).
Monitor legislative and administrative action on chemical facilities regulation; Monitor legislative and administrative action related to the Toxic Substances Control Act. S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act and H.R. 2576, the TSCA Modernization Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON SOFTWARE INTERNATIONAL via STANTON PARK GROUP
2015 · third_quarter · Q3
benefits of technology in eliminating waste, fraud and abuse from the National School Lunch Program administered by the USDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSIGNIA HEALTH via STANTON PARK GROUP
2015 · third_quarter · Q3
increasing awareness regarding the ability of the Patient Activation Measurement (PAM) to reduce healthcare costs and increase effectiveness; HR 2 - the Medicare Access and CHIP Reauthorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via STANTON PARK GROUP
2015 · third_quarter · Q3
access to rare and orphan disease therapeutics; newborn screening for heritable disorders; H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; HR 6, the 21st Century Cures initiative; DEA processes and re-exportation; ADHD awareness; patent reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) via STANTON PARK GROUP
2015 · third_quarter · Q3
Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via STANTON PARK GROUP
2015 · third_quarter · Q3
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JUNIPER NETWORKS (US), INC. via STANTON PARK GROUP
2015 · third_quarter · Q3
cybersecurity, protection of critical infrastructure, and risk management of government and industry supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOVERNMENT TRANSACTION SERVICES via STANTON PARK GROUP
2015 · third_quarter · Q3
administrative/paperwork burden reduction by simplifying and streamlining the federal grant process
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCRIBEAMERICA via STANTON PARK GROUP
2015 · third_quarter · Q3
raising awareness regarding the role and benefits of medical scribes, and opportunities to achieve efficiencies in the healthcare delivery system by using scribes; ACA implementation issues; promoting scribes as an efficiency tool for the Veterans Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRIMBLE NAVIGATION LIMITED via STANTON PARK GROUP
2015 · third_quarter · Q3
spectrum issues impacting the reliability of viability of the Global Positioning System (GPS); all provisions related to GPS interface; Financial Services and General Government Appropriations (HR 2995)
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE
WESTERN FUELS ASSOCIATION, INC. via STANTON PARK GROUP
2015 · third_quarter · Q3
captive shipper issues
coal issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLGA FOUNDATION via STANTON PARK GROUP
2015 · third_quarter · Q3
NIH research on slow growing PLGA childhood brain tumors; issues impacting pediatric cancer research and treatments; NIH funding in the FY2016 Labor, Health and Education Appropriations Act. Access to therapies and FDA approval pathways for rare disease HR 3020/S 1695, the FY2016 Labor HHS Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR QUALITY HOME HEALTHCARE (FORMERLY HOME HEALTH ADVOCACY COALITION via STANTON PARK GROUP
2015 · third_quarter · Q3
protecting rural access to skilled home health services; elimination of waste, fraud and abuse; protecting reimbursement for home health services through the Medicare program; HR 2 (the Medicare Access and CHIP Reauthorization Act). Value Based Purchasing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOLCIM (US) INC via STANTON PARK GROUP
2015 · third_quarter · Q3
energy intensive industries
infrastructure spending; concrete and cement standards for construction; reauthorization of transportation research programs; closure of the Upper St. Anthony Falls lock and dam, as enacted in the Water Resources and Development Act; the Federal Motor Carrier Safety Administration (FMCSA) rest-break and hours-of-service requirements for ready mix concrete drivers S. 1732, the Comprehensive Transportation and Consumer Protection Act of 2015
cement industry standards for various emissions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HENDERSON-COLUMBIA CORP. AND THE ESTATE OF WILBUR C. HENDERSON via STANTON PARK GROUP
2015 · third_quarter · Q3
oversight of the EPA and the Superfund program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FIBERTOWER via STANTON PARK GROUP
2015 · third_quarter · Q3
spectrum and issues impacting fixed wireless private carriers who offer broadband transport and backhaul infrastructure services. E-rate program and partnerships with schools and libraries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELPHI TECHNOLOGIES (FORMERLY DELPHI CORPORATION) via STANTON PARK GROUP
2015 · third_quarter · Q3
Trade Promotion Authority, including HR 2146, Bipartisan Congressional Trade Priorities and Accountability Act of 2015
energy and water appropriations; energy efficiency research and development
vehicle safety issues, vehicle safety technologies including crash avoidance/active safety technologies. Safety Through Informed Consumers (STICRS) HR 2702/S1535
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE